Anti-tumour effects by a trimodal combination of temozolomide, meloxicam and X-rays in cultures of human glioma cells

Krista A. Van Nifterik, Jaap Van Den Berg, Ben J. Slotman, Johannes Van Rijn
2010 International Journal of Radiation Biology  
Purpose: To investigate the possible cytotoxic interactions between the chemotherapeutic drug temozolomide (TMZ) and the cyclooxygenase-2 inhibitor meloxicam (MLC) or of both drugs combined with X-rays in three human glioma cell lines (D384, Hs 683 and U251). Materials and methods: Cells were exposed to TMZ (96 hours) and MLC was coincubated during the last 24 h. Thereafter, cells were irradiated with X-rays and plated for a clonogenic assay. Total cell numbers and the numbers of surviving
more » ... were determined to study the recovery of the cell populations (up until 19 days) following different combinations of TMZ, MLC and X-rays. Results: The combination of MLC and TMZ caused an enhanced cytotoxic effect in D384 and Hs 683. Various treatment combinations demonstrated significant radiation enhancement in all three cell lines. Long-term observations of D384 cells demonstrated that the repopulation rates of the surviving cells are far less affected by the various treatment protocols than those from the non-surviving cells. Conclusions: The present study demonstrates that a combination of TMZ and MLC resulted in a significant potentiation of their cytotoxicity in D384 and Hs683. The combination of these two drugs can also cause considerable enhancement of the radiation response in human glioma cell lines, although only D384 cells benefit from trimodal over bimodal treatment. Chapter 6
doi:10.3109/09553002.2010.519423 pmid:21067299 fatcat:no5llzqttvhktg3qcuu347qyzm